Enass Najem Oubaid

Enass Najem Oubaid

Auto-generated profile, based on publicly available information

Enass Najem Oubaid

Department of Pharmacognosy, College of Pharmacy, University of Babylon, Babylon, Iraq

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2025 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
ARAbdulla Kadhim Raheem
Abdulla Kadhim Raheem
AAAhmed Rahmah Abu-Raghif
Ahmed Rahmah Abu-Raghif
AAAlaa Hamza Abbas
Alaa Hamza Abbas
HRHayder Ridha-Salman
Hayder Ridha-Salman
EOEnass Najem Oubaid
Enass Najem Oubaid

6 March 2023 in Pharmacia
Verified
Journal Article
Open access
PDF file
EOEnass Najem Oubaid
Enass Najem Oubaid
AAAhmed Abu-Raghif
Ahmed Abu-Raghif
IAIsraa Mahdi Al-Sudani
Israa Mahdi Al-Sudani
Objectives: This study was carried out to explore the possible anti-inflammatory effect of ibudilast on acetic acid-induced colitis in rats. Methods: Fifty adult Wistar rats were separated into 5 groups, including the control group, acetic acid group, acetic acid + vehicle, acetic acid + sulfasalazine (100 mg/kg/day)group, and acetic acid + ibudilast (30 mg/kg/day) group. Colitis was induced in rats by the inter-rectal installation of 2 ml of 4% (v/v) acetic acid. Sulfasalazine and ibudilast were administered orally for ten days after 2 hours of induction. Results: The treatment with ibudilast significantly reduced disease activity index (DAI), macroscopic colonic scores (MAC), and histopathological changes induced by acetic acid. Also, ibudilast markedly decreased the expression of proinflammatory markers (TNF-α and IL-1β) in colonic tissue. Moreover, ibudilast inhibited myeloperoxidase (MPO) enzyme activity that was increased by acetic acid. Conclusion: Therefore, ibudilast may have a therapeutic effect in the management of ulcerative colitis.

1 January 2026 in Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
Verified
Journal Article
Open access
PDF file
EOEnass Najem Oubaid
Enass Najem Oubaid
NHNoor Ali Hussein
Noor Ali Hussein
GNGhada Hamid Naji
Ghada Hamid Naji
FAFatima Adnan Alzubaidi
Fatima Adnan Alzubaidi
Background: Ulcerative colitis is a persistent mucosal inflammation of the bowel that impacts a high portion of the population worldwide. It often presents with symptoms of severe diarrhea, weight reduction, and perianal bleeding. Objective: To investigate the potential anti-inflammatory effects of azilsartan on dextran sulfate-induced ulcerative colitis in rats. Methods: Forty healthy adult albino rats were divided into 4 groups, as follows: the normal control group, the DSS group, DSS+ prednisolone (10 mg/kg/day) group, and DSS+azilsartan (10 mg/kg/day) group. The colitis induction was prompted in rats by administering 3% DSS in drinking water for 7 days. Results: The administration of azilsartan notably decreased edema index, spleen index, macroscopic changes scores, and microscopic changes scores that were produced by DSS. Additionally, azilsartan markedly reduced the proinflammatory cytokine expression, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in colon tissue. Furthermore, azilsartan significantly attenuated oxidative stress in colonic tissue by decreasing up-regulated myeloperoxidase (MPO) enzyme activity and increasing down-regulated catalase antioxidant activity. Conclusions: Azilsartan may have an effective role in the treatment of ulcerative colitis.

5 May 2024 in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Verified
Journal Article
Closed access
FAFatima Adnan Alzubaidi
Fatima Adnan Alzubaidi
EOEnass Najem Oubaid
Enass Najem Oubaid
ZSZahraa I. J. Shubber
Zahraa I. J. Shubber
HAHussam Al-Humadi
Hussam Al-Humadi
RARafal J. Al-Saigh
Rafal J. Al-Saigh
Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) has been documented all over the world. Currently, limited evidence exists concerning the protec¬tion afforded by the COVID-19 vaccination against reinfection with SARS-CoV-2. This case-control study was per¬formed in order to assess the association between COVID-19 vaccination and SARS-CoV-2 reinfection in the Babil Province; the study used an electronic questionnaire. The infected patients were 115 (aged ≥18 years) and were confirmed by a positive PCR and/or a CT scan, they were either fully vaccinated or not with a second dose of a (Pfizer, AstraZeneca, or Sinopharm) vaccine before the reinfection date, and they were compared with 300 control partici¬pants. The study’s findings revealed that the unvaccinated individuals had 4.5 times the odds of reinfection compared to those who were fully vaccinated, without preference for the manufacturer of the vaccine. The conclusion suggests that getting fully vaccinated against COVID-19 can significantly reduce the likelihood of reinfection, can enhance overall protection, and can minimize the risk of future infections.